Related Experiment Video

Updated: Aug 6, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Targeting epidermal growth factor receptor in lung cancer

José Baselga1, Joan Albanell

  • 1Medical Oncology Service, Hospital General Universitari Vall d'Hebron, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain. baselga@hg.vhebron.es

Current Oncology Reports
|June 5, 2002
PubMed

Insights

Epidermal growth factor receptor (EGFR) targeted therapies show promise for non-small-cell lung cancer (NSCLC). Studies evaluate EGFR tyrosine kinase inhibitors like ZD1839 and OSI-774 for advanced NSCLC and as first-line chemotherapy additions.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) remains a significant health challenge.
  • Targeted therapies offer a promising avenue for NSCLC treatment.
  • Epidermal growth factor receptor (EGFR) is a key target in NSCLC.

Purpose of the Study:

  • To review the clinical development and activity of EGFR-targeting agents for NSCLC.
  • To assess the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in advanced NSCLC.
  • To explore the potential of EGFR TKIs as first-line treatment and in neoadjuvant settings.

Main Methods:

  • Review of recent clinical studies on anti-EGFR therapies for NSCLC.
  • Evaluation of antitumor responses to EGFR TKIs (ZD1839, OSI-774) in chemotherapy-refractory NSCLC.
  • Assessment of survival benefits from combining EGFR TKIs with standard chemotherapy.

Main Results:

  • Antitumor responses observed with EGFR TKIs in advanced, chemotherapy-refractory NSCLC.
  • Ongoing evaluation of EGFR TKIs for survival benefits in first-line settings.
  • Research into neoadjuvant treatment and chemoprevention strategies using EGFR inhibitors.

Conclusions:

  • EGFR-targeting agents, including TKIs and monoclonal antibodies, are highly promising for NSCLC treatment.
  • Further research is crucial to establish the role of these agents in various NSCLC treatment paradigms.
  • The development pipeline for EGFR-directed therapies is expanding, offering new hope for NSCLC patients.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...